Sciclone Pharmaceuticals Stock Probability Of Bankruptcy
SciClone Pharmaceuticals fundamentals help investors to digest information that contributes to SciClone Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of SciClone Stock. The fundamental analysis module provides a way to measure SciClone Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SciClone Pharmaceuticals stock.
SciClone |
SciClone Pharmaceuticals Company odds of distress Analysis
SciClone Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability_Of_Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current SciClone Pharmaceuticals Probability Of Bankruptcy | Over 100% |
Most of SciClone Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SciClone Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of SciClone Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting SciClone Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of SciClone Pharmaceuticals financial health.
Please note, there is a significant difference between SciClone Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if SciClone Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SciClone Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, SciClone Pharmaceuticals has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the sector and 160.42% higher than that of the Probability Of Bankruptcy industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
SciClone Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SciClone Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SciClone Pharmaceuticals could also be used in its relative valuation, which is a method of valuing SciClone Pharmaceuticals by comparing valuation metrics of similar companies.SciClone Pharmaceuticals is currently under evaluation in probability of bankruptcy category among related companies.
SciClone Fundamentals
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 25.82 % | |||
| Current Valuation | 422 M | |||
| Shares Outstanding | 52.19 M | |||
| Shares Owned By Insiders | 10.03 % | |||
| Shares Owned By Institutions | 79.96 % | |||
| Number Of Shares Shorted | 1.21 M | |||
| Price To Earning | 13.75 X | |||
| Price To Book | 2.33 X | |||
| Price To Sales | 3.38 X | |||
| Revenue | 172.02 M | |||
| Gross Profit | 137.2 M | |||
| EBITDA | 45.42 M | |||
| Net Income | 43.31 M | |||
| Cash And Equivalents | 157.33 M | |||
| Cash Per Share | 3.01 X | |||
| Total Debt | 2.73 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 8.36 X | |||
| Book Value Per Share | 3.53 X | |||
| Cash Flow From Operations | 35.74 M | |||
| Short Ratio | 2.34 X | |||
| Earnings Per Share | 0.81 X | |||
| Price To Earnings To Growth | 0.84 X | |||
| Number Of Employees | 590 | |||
| Beta | 1.25 | |||
| Market Capitalization | 581.94 M | |||
| Total Asset | 216.62 M | |||
| Retained Earnings | (115.06 M) | |||
| Working Capital | 131.7 M | |||
| Current Asset | 168.52 M | |||
| Current Liabilities | 36.82 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards SciClone Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, SciClone Pharmaceuticals' short interest history, or implied volatility extrapolated from SciClone Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |